Daewha Pharmaceutical made IND application of Phase 2 clinical trial for breast cancer to FDA
Daehwa Pharmaceutical announced on the 18th that the company completed the IND(Investigational New Drug) application process for a Phase 2 clinical trial of paclitaxel, an oral anti-cancer drug(Korean product name: Liporaxel Soln), to conduct a clinical trial on breast cancer patients in the U.S....
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
